Latest Benign Prostatic Hyperplasia (BPH) News
PUL involves placement of small permanent metallic implants into the prostate that lift the lateral lobes away from the urethra and remove obstruction.
NSAID users had a 2-fold increased risk of BPH medication use, 59% increased risk of a recorded BPH diagnosis, and 61% increased risk for BPH surgery.
Average International Prostate Symptom Score remained low 5 years after the PVP laser procedure.
Researchers identified a predictor of new-onset UI after HoLEP that may aid urologists in clinical practice.
In a study, 81.1% of men were able to void after an average of 28 days after treatment.
The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.
In a study, 86% of prostatic urethral lift patients experienced symptom relief in the first month.
Findings emerged from an analysis of data from 2588 men who participated in the REDUCE trial.
Study confirms small, but significant increases in the risks of these mental health problems among men taking the medication.
Longer use of finasteride at a dosage of 1.25 mg/day or less among men younger than 42 years is associated with greater risk, study finds.
The finasteride and dutasteride recipients had significantly less mean blood loss than the placebo group.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
Poor baseline functional status and having a Foley catheter preoperatively were associated with greater risk of TURP or TULIP failure.
New findings confirm previous reports.
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)